Published in Am J Pathol on December 01, 2004
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc Natl Acad Sci U S A (2007) 1.29
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 1.12
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest (2008) 1.01
Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis (2012) 0.97
Pathologic patterns of interleukin 10 expression--a review. Biochem Med (Zagreb) (2015) 0.97
Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol (2006) 0.96
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol (2011) 0.95
IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol (2011) 0.94
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol (2015) 0.92
Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology (2013) 0.92
Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology (2012) 0.91
Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res (2011) 0.89
Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14(+) Cells at the Cross-Roads of Immune Activation and Suppression. Front Immunol (2013) 0.87
The transmembrane protein of the human endogenous retrovirus--K (HERV-K) modulates cytokine release and gene expression. PLoS One (2013) 0.85
Cytomegalovirus and tumors: two players for one goal-immune escape. Open Virol J (2011) 0.84
Regulatory T cells: present facts and future hopes. Med Microbiol Immunol (2006) 0.83
Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets Ther (2012) 0.82
Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models. Oncoimmunology (2012) 0.80
Immunological cells and functions in Gaucher disease. Crit Rev Oncog (2013) 0.80
T-cell tolerance in cancer. Immunotherapy (2013) 0.79
CD4(+)FOXP3(+) T regulatory cells decrease and CD3(+)CD8(+) T cells recruitment in TILs from melanoma metastases after electrochemotherapy. Clin Exp Metastasis (2016) 0.79
Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes. Clin Dev Immunol (2011) 0.78
Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine (2013) 0.78
P2X7 receptor activation impairs exogenous MHC class I oligopeptides presentation in antigen presenting cells. PLoS One (2013) 0.76
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology (2010) 0.76
Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape. J Immunol (2016) 0.76
Dietary agents in cancer prevention: an immunological perspective. Photochem Photobiol (2012) 0.76
Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function. PLoS One (2015) 0.75
Motolimod effectively drives immune activation in advanced cancer patients. Oncoimmunology (2016) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature (1994) 6.13
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med (1996) 5.29
CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature (1992) 5.25
Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol (1997) 5.21
The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol (1999) 4.10
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A (1998) 2.96
Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol (2001) 2.89
Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood (1999) 2.47
Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol (1993) 2.20
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ alpha beta T cell pool. J Immunol (1999) 1.96
Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell (1981) 1.92
Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol (1999) 1.89
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer (1997) 1.86
Molecular recognition of lipid antigens by T cell receptors. J Exp Med (1999) 1.65
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res (2001) 1.51
Role of tumor-associated gangliosides in cancer progression. Biochimie (2003) 1.51
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50
T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol (1999) 1.46
Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol (1995) 1.43
IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J Immunol (2000) 1.42
The CD1 family of lipid antigen-presenting molecules. Immunol Today (1998) 1.42
A monoclonal antibody recognizing a human thymus leukemia-like antigen associated with beta 2-microglobulin. Eur J Immunol (1982) 1.39
Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer (1994) 1.35
Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood (2004) 1.35
Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int Immunol (1994) 1.32
CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J Immunol (1999) 1.32
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A (1987) 1.30
Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer (1998) 1.28
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res (1995) 1.24
Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem (1979) 1.21
Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol (2000) 1.20
Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. Proc Natl Acad Sci U S A (1989) 1.20
Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother (2003) 1.17
Gangliosides of human melanoma. J Natl Cancer Inst (1987) 1.17
B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol (1995) 1.15
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol (2003) 1.15
Structure and function of the CD1 family of MHC-like cell surface proteins. Immunol Rev (1995) 1.11
Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol (2001) 1.10
Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer (1985) 1.10
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer (2000) 1.09
Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother (1997) 1.07
Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res (1989) 1.04
Gangliosides as therapeutic targets for cancer. BioDrugs (2003) 1.02
Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest (2001) 0.98
Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol (1997) 0.98
Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer (1996) 0.93
Ganglioside vaccines with emphasis on GM2. Semin Oncol (1998) 0.91
Differential effects of interleukin-10 on the expression of HLA class II and CD1 molecules induced by granulocyte/macrophage colony-stimulating factor/interleukin-4. Eur J Immunol (1995) 0.89
Ganglioside metabolism: enzymology, topology and regulation. Prog Brain Res (1994) 0.89
Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet (1989) 0.88
IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol (1999) 0.88
Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules? Int J Cancer (2002) 0.86
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer (2000) 0.85
Immune escape mechanisms in malignant melanoma. Int J Mol Med (1999) 0.85
Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J Invest Dermatol (2001) 0.84
Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol (1992) 0.84
The CD1 family and T cell recognition of lipid antigens. Tissue Antigens (2002) 0.83
Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group. Int J Cancer (1991) 0.82
Bacillus Calmette-Guerin down-regulates CD1b induction by granulocyte-macrophage colony stimulating factor in human peripheral blood monocytes. J Chemother (2001) 0.78
Studies of a ganglioside fraction extracted from human malignant melanoma. Biochimie (1976) 0.76
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet (2012) 6.97
The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet (2011) 5.95
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol (2006) 2.85
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet (2007) 2.78
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med (2007) 2.70
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med (2004) 2.63
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet (2008) 2.42
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest (2004) 2.34
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet (2011) 2.21
Psoriasis. Annu Rev Pathol (2011) 2.21
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res (2002) 2.06
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med (2012) 1.81
Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol (2011) 1.79
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One (2011) 1.71
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
Dyscrasias with "undetermined significance". Arch Dermatol (2005) 1.70
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol (2006) 1.70
Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61
Angiolymphoid hyperplasia with eosinophilia: evidence for a T-cell lymphoproliferative origin. Hum Pathol (2002) 1.58
Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med (2011) 1.56
Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. Arch Dermatol (2010) 1.55
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol (2002) 1.54
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst (2005) 1.46
Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol (2007) 1.46
Hypertext atlas of dermatopathology with expert system for epithelial tumors of the skin. J Cutan Pathol (2005) 1.40
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer (2006) 1.38
The multitasking organ: recent insights into skin immune function. Immunity (2011) 1.38
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
Gene expression changes with age in skin, adipose tissue, blood and brain. Genome Biol (2013) 1.34
The cytokine and chemokine network in psoriasis. Clin Dermatol (2007) 1.31
Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 1.27
The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol (2007) 1.27
Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat Cell Biol (2008) 1.27
Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells (2012) 1.26
TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol (2013) 1.20
Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer (2003) 1.15
Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther (2005) 1.12
IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 1.12
New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol (2002) 1.11
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol (2007) 1.10
Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant (2009) 1.07
Fucosyltransferase VII-deficient mice with defective E-, P-, and L-selectin ligands show impaired CD4+ and CD8+ T cell migration into the skin, but normal extravasation into visceral organs. J Immunol (2002) 1.07
A systems model for immune cell interactions unravels the mechanism of inflammation in human skin. PLoS Comput Biol (2010) 1.07
Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Hum Mol Genet (2012) 1.06
Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer (2003) 1.06
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood (2003) 1.05
Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype. PLoS One (2012) 1.04
Skin cancer and immunosuppression. Crit Rev Oncol Hematol (2005) 1.04
Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother (2011) 1.03
Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation (2004) 1.02
Dermatology online with interactive technology (DOIT). Curr Probl Dermatol (2003) 1.00
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother (2008) 0.99
A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol (2008) 0.99
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol (2003) 0.98
Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology (2003) 0.98
Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis (2012) 0.97
Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res (2010) 0.96
Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood (2004) 0.96
Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood (2003) 0.96
Spectral morphological analysis of skin lesions with a polarization multispectral dermoscope. Opt Express (2013) 0.96
Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis (2013) 0.95
CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol (2005) 0.95
The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol (2013) 0.95
Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol (2008) 0.94
Massive recruitment of type I interferon producing plasmacytoid dendritic cells in varicella skin lesions. J Invest Dermatol (2006) 0.94
High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother (2003) 0.94
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide. PLoS One (2010) 0.94
Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood (2002) 0.93
Expression of Notch-1 and alteration of the E-cadherin/beta-catenin cell adhesion complex are observed in primary cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). Mod Pathol (2009) 0.92
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One (2011) 0.92
A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J Immunol (2007) 0.92
The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep (2010) 0.92